1446 related articles for article (PubMed ID: 29446063)
1. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
[TBL] [Abstract][Full Text] [Related]
3. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
[TBL] [Abstract][Full Text] [Related]
4. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
[TBL] [Abstract][Full Text] [Related]
5. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
Parasuraman S; Thiel E; Park J; Teschemaker A
J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
[TBL] [Abstract][Full Text] [Related]
6. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
[TBL] [Abstract][Full Text] [Related]
7. Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine.
Gilligan AM; Foster SA; Sainski-Nguyen A; Sedgley R; Smith D; Morrow P
J Occup Environ Med; 2018 Dec; 60(12):1120-1127. PubMed ID: 30199470
[TBL] [Abstract][Full Text] [Related]
8. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
9. Incremental direct and indirect cost burden attributed to endometriosis surgeries in the United States.
Soliman AM; Taylor HS; Bonafede M; Nelson JK; Castelli-Haley J
Fertil Steril; 2017 May; 107(5):1181-1190.e2. PubMed ID: 28476181
[TBL] [Abstract][Full Text] [Related]
10. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
11. Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.
Silberstein SD; Lee L; Gandhi K; Fitzgerald T; Bell J; Cohen JM
Headache; 2018 Nov; 58(10):1579-1592. PubMed ID: 30375650
[TBL] [Abstract][Full Text] [Related]
12. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
Ford JH; Ye W; Nichols RM; Foster SA; Nelson DR
J Med Econ; 2019 Sep; 22(9):849-858. PubMed ID: 30977712
[No Abstract] [Full Text] [Related]
14. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
15. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
[No Abstract] [Full Text] [Related]
16. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
Tepper SJ; Schwedt TJ; Vo P; Thompson J; Joshi P; Abdrabboh A; Ferraris M; Tiwari S
Headache; 2023; 63(10):1423-1436. PubMed ID: 37655551
[TBL] [Abstract][Full Text] [Related]
18. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of migraine in Latvia and Lithuania: direct and indirect costs.
Lublóy Á
BMC Public Health; 2019 Sep; 19(1):1242. PubMed ID: 31500616
[TBL] [Abstract][Full Text] [Related]
20. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
